Near-term hiccups to have limited impact on Abbott India's growth: Experts

Despite the muted result and near term worries, the multinational drug major, India's second largest by market share is expected to post strong growth led by power brands and new launches

The Abbott India stock is down about 7 per cent from its highs this week on lower than expected March quarter results and muted near-term outlook. The company is likely to report a soft June quarter given the Covid-19 outbreak which has impacted raw material availability, supply chain as well as demand. 

The demand worries are visible in the sales numbers for April and May with the company reporting a 8 per cent decline each year on year. However, the company outperformed the market which fell 9-11 per cent over the last two month. The decision by the Indian drug